Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Gyroscope

18.12.2020

Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases

Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope has an exclusive option to the intellectual property associated with, and arising from, the research conducted under the agreement.
Gyroscope

02.12.2020

Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to its Board of Directors

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows, and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately.
Gyroscope

11.11.2020

Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of the Phase II HORIZON trial evaluating GT005 in people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The first patient to receive GT005 in HORIZON was enrolled and dosed in the United States by Jeffrey Heier, M.D., at Ophthalmic Consultants of Boston. HORIZON is a randomised controlled Phase II trial evaluating the safety and effectiveness of GT005 in a broad population of people with GA secondary to dry AMD. GT005 is an investigational one-time AAV-based gene therapy that is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I (CFI) protein, and is intended to slow the progression of GA that can lead to blindness.
Gyroscope

28.10.2020

Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the first surgery using its proprietary OrbitTM Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been conducted in the ongoing Phase I/II FOCUS trial. The surgery was conducted in the United States by Jeffrey Heier, M.D., at Ophthalmic Consultants of Boston.
Gyroscope

22.09.2020

Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration (1)

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is intended to slow the progression of GA that can lead to blindness.
Gyroscope

11.09.2020

Gyroscope Therapeutics Announces Appointment of Sean Bohen to the Board of Directors (1)

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that biotech industry veteran Sean Bohen, M.D., Ph.D., has been appointed to the Gyroscope Board of Directors, effective immediately. Dr. Bohen will also serve as Chair of the Board’s Research and Development Committee. Dr. Bohen brings more than 30 years of experience in the discovery and development of new medicines. Over the course of his career, he has made significant contributions to the early- and late-stage development of numerous FDA-approved drugs.
Gyroscope

25.08.2020

Gyroscope Therapeutics Announces FDA Clearance for Orbit Subretinal Delivery System

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for the Orbit™ Subretinal Delivery System (Orbit SDS). The Orbit SDS is indicated for microinjection into the subretinal space at the back of the eye. The microinjection procedure is designed to avoid damaging the structure of the eye by preventing the need for a vitrectomy, a procedure that involves removing the vitreous (the gel-like substance that fills the eye). The approach also eliminates the need to create a retinotomy (a hole in the retina) in order to access the subretinal space. This clearance is based on injection of Balanced Salt Solution (BSS) or BSS PLUS®.*
Gyroscope

13.08.2020

Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Dry AMD is a leading cause of permanent vision loss in people over the age of 50. GT005 is a one-time AAV-based gene therapy that is delivered under the retina. The goal of the Phase II clinical trial programme is to determine if GT005 has the potential to slow the progression of GA.
Gyroscope

04.08.2020

Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to its Clinical and Scientific Advisory Boards

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the appointment of leading experts in retinal disease, gene therapy and the complement system to its Clinical and Scientific Advisory Boards. The newly appointed boards will help guide the development of the company's lead investigational gene therapy, GT005, a one-time therapy being developed to potentially slow the progression of dry age-related macular degeneration (AMD), as well as novel gene therapy delivery systems and additional pipeline candidates.
Gyroscope

14.02.2020

Gyroscope Therapeutics strengthens leadership team ahead of next stage of company growth

Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, announces the strengthening of its leadership team with the hiring of Dr. Nadia Waheed from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO) and the promotion of Dr. Jane Hughes, formerly VP Translational Research, to Chief Scientific Officer (CSO).

Load More